12:00 AM
 | 
Jul 25, 2016
 |  BC Week In Review  |  Company News  |  Sales & Marketing

United Therapeutics sales and marketing update

The U.K.’s NICE issued final draft guidance recommending against Unituxin dinutuximab from United Therapeutics to treat high-risk neuroblastoma in combination with GM-CSF, IL-2 and isotretinoin in patients ages one to 17 whose disease has responded at least partially to...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >